Table 1.
BET protein inhibitors in early phase clinical trials.
| ClinicalTrials.gov identifier | Condition | Drug | Sponsor | Phase | Start date |
|---|---|---|---|---|---|
| NCT01587703 | Solid tumours and multiple myeloma | I-BET762 | GlaxoSmithKline | I | March 2012 |
| NCT01943851 | Haematological malignancies | I-BET762 | GlaxoSmithKline | I | May 2014 |
| NCT02157636 | Multiple myeloma | CPI-0610 | Constellation Pharmaceuticals | I | July 2014 |
| NCT01949883 | Lymphoma | CPI-0610 | Constellation Pharmaceuticals | I | September 2013 |
| NCT02158858 | Acute leukaemia, myelodysplastic syndrome, or myelodysplastic / myeloproliferative neoplasms | CPI-0610 | Constellation Pharmaceuticals | I | July 2014 |
| NCT01713582 | Haematological malignancies | OTX015 | OncoEthix | I | December 2012 |